A Phase 1b Trial in Stage II-III Urothelial Cancer to Explore Pre-operative Immunotherapy
Latest Information Update: 07 Mar 2025
At a glance
- Drugs Nivolumab (Primary)
- Indications Urogenital cancer
- Focus Therapeutic Use
- Acronyms TURANDOT
- Sponsors 4SC AG
Most Recent Events
- 04 Mar 2025 Status changed from active, no longer recruiting to completed.
- 05 Oct 2023 Planned End Date changed from 30 Jul 2024 to 2 Jun 2026.
- 09 May 2023 Planned End Date changed from 30 Apr 2023 to 30 Jul 2024.